Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study.

Jung M, Ellinger J, Gevensleben H, Syring I, Lüders C, de Vos L, Pützer S, Bootz F, Landsberg J, Kristiansen G, Dietrich D.

Clin Chem. 2019 Jan 9. pii: clinchem.2018.297549. doi: 10.1373/clinchem.2018.297549. [Epub ahead of print]

PMID:
30626634
2.

Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma.

Zhao C, Tolkach Y, Schmidt D, Toma M, Muders MH, Kristiansen G, Müller SC, Ellinger J.

World J Urol. 2018 Nov 28. doi: 10.1007/s00345-018-2575-1. [Epub ahead of print]

PMID:
30488095
3.

Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.

Müller T, Tolkach Y, Stahl D, Steiner S, Hauser S, Ellinger J, Rabien A, Ralla B, Jung K, Stephan C, Kristiansen G.

Clin Genitourin Cancer. 2018 Oct 23. pii: S1558-7673(18)30427-0. doi: 10.1016/j.clgc.2018.10.008. [Epub ahead of print]

PMID:
30448104
4.

tRNA-halves are prognostic biomarkers for patients with prostate cancer.

Zhao C, Tolkach Y, Schmidt D, Muders M, Kristiansen G, Müller SC, Ellinger J.

Urol Oncol. 2018 Nov;36(11):503.e1-503.e7. doi: 10.1016/j.urolonc.2018.08.003. Epub 2018 Sep 9.

PMID:
30209018
5.

The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy.

Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J.

Oncol Lett. 2018 Sep;16(3):3013-3021. doi: 10.3892/ol.2018.9014. Epub 2018 Jun 25.

6.

Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study.

Gierth M, Zeman F, Denzinger S, Vetterlein MW, Fisch M, Bastian PJ, Syring I, Ellinger J, Müller SC, Herrmann E, Gilfrich C, May M, Pycha A, Wagenlehner FM, Vallo S, Bartsch G, Haferkamp A, Grimm MO, Roigas J, Protzel C, Hakenberg OW, Fritsche HM, Burger M, Aziz A, Mayr R.

Urol Int. 2018;101(1):16-24. doi: 10.1159/000488466. Epub 2018 May 2.

PMID:
29719296
7.

The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells.

Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Müller SC, Kristiansen G, Ellinger J.

Ann Diagn Pathol. 2018 Jun;34:18-26. doi: 10.1016/j.anndiagpath.2017.12.008. Epub 2017 Dec 20.

PMID:
29661722
8.

Fungaemia caused by obstructive renal candida bezoars leads to bilateral chorioretinitis: a case report.

Stein J, Latz S, Ellinger J, Fechner G, Safi M, Krausewitz P, Müller S, Weyer K, Müller SC.

BMC Urol. 2018 Mar 16;18(1):21. doi: 10.1186/s12894-018-0335-6.

9.

YRNA expression in prostate cancer patients: diagnostic and prognostic implications.

Tolkach Y, Niehoff EM, Stahl AF, Zhao C, Kristiansen G, Müller SC, Ellinger J.

World J Urol. 2018 Jul;36(7):1073-1078. doi: 10.1007/s00345-018-2250-6. Epub 2018 Feb 28.

PMID:
29492585
10.

Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma.

Heinemann FG, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G, Müller SC, Ellinger J.

Clin Epigenetics. 2018 Jan 23;10:11. doi: 10.1186/s13148-018-0444-9. eCollection 2018.

11.

The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma.

Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J, Syring I.

Cancer Biomark. 2018;21(4):839-847. doi: 10.3233/CBM-170757.

PMID:
29400661
12.

The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer.

Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J.

Anticancer Res. 2017 Dec;37(12):6685-6695.

PMID:
29187445
13.

YRNA expression predicts survival in bladder cancer patients.

Tolkach Y, Stahl AF, Niehoff EM, Zhao C, Kristiansen G, Müller SC, Ellinger J.

BMC Cancer. 2017 Nov 10;17(1):749. doi: 10.1186/s12885-017-3746-y.

14.

Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression.

Bläsius FM, Meller S, Stephan C, Jung K, Ellinger J, Glocker MO, Thiesen HJ, Tolkach Y, Kristiansen G.

Oncotarget. 2017 Aug 24;8(43):75076-75086. doi: 10.18632/oncotarget.20507. eCollection 2017 Sep 26.

15.

High grade adenocarcinoma in the ectopic prostate accompanied by a low grade adenocarcinoma in the orthotopic prostate: an unusual diagnostic pitfall.

Tolkach Y, Ellinger J, Müller S, Kristiansen G.

Pathology. 2017 Oct;49(6):665-668. doi: 10.1016/j.pathol.2017.06.005. Epub 2017 Aug 19. No abstract available.

PMID:
28830691
16.

Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.

Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, Rabien A, Feldmann G, Brossart P, Bundschuh RA, Ahmadzadehfar H, Essler M, Toma M, Müller SC, Ellinger J, Hauser S, Kristiansen G.

J Urol. 2018 Feb;199(2):370-377. doi: 10.1016/j.juro.2017.08.079. Epub 2017 Aug 19.

PMID:
28827104
17.

5'-tRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma.

Zhao C, Tolkach Y, Schmidt D, Kristiansen G, Müller SC, Ellinger J.

J Urol. 2018 Feb;199(2):378-383. doi: 10.1016/j.juro.2017.07.082. Epub 2017 Jul 29.

PMID:
28765068
18.

YRNA Expression Profiles are Altered in Clear Cell Renal Cell Carcinoma.

Nientiedt M, Schmidt D, Kristiansen G, Müller SC, Ellinger J.

Eur Urol Focus. 2018 Mar;4(2):260-266. doi: 10.1016/j.euf.2016.08.004. Epub 2016 Aug 23.

PMID:
28753785
19.

Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma.

Brüggemann M, Gromes A, Poss M, Schmidt D, Klümper N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC, Ellinger J.

Transl Oncol. 2017 Aug;10(4):661-668. doi: 10.1016/j.tranon.2017.06.002. Epub 2017 Jun 30.

20.

[Molecular biomarkers and prognostic factors for prostate cancer].

Kretschmer A, Tolkach Y, Ellinger J, Kristiansen G.

Urologe A. 2017 Jul;56(7):933-944. doi: 10.1007/s00120-017-0418-0. Review. German.

PMID:
28573413
21.

Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.

Schröck A, Leisse A, de Vos L, Gevensleben H, Dröge F, Franzen A, Wachendörfer M, Schröck F, Ellinger J, Teschke M, Wilhelm-Buchstab T, Landsberg J, Holdenrieder S, Hartmann G, Field JK, Bootz F, Kristiansen G, Dietrich D.

Clin Chem. 2017 Jul;63(7):1288-1296. doi: 10.1373/clinchem.2016.270207. Epub 2017 May 17.

22.

Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.

Klümper N, Syring I, Vogel W, Schmidt D, Müller SC, Ellinger J, Shaikhibrahim Z, Brägelmann J, Perner S.

Front Med (Lausanne). 2017 Mar 17;4:30. doi: 10.3389/fmed.2017.00030. eCollection 2017.

23.

[When is surgical resection of the primary tumor indicated in metastatic urothelial carcinoma of the bladder and what is the scientific rationale?]

Ellinger J, Hauser S, Kübler H, Müller SC.

Urologe A. 2017 May;56(5):564-569. doi: 10.1007/s00120-017-0360-1. Review. German.

PMID:
28314967
24.

ISL1 is a major susceptibility gene for classic bladder exstrophy and a regulator of urinary tract development.

Zhang R, Knapp M, Suzuki K, Kajioka D, Schmidt JM, Winkler J, Yilmaz Ö, Pleschka M, Cao J, Kockum CC, Barker G, Holmdahl G, Beaman G, Keene D, Woolf AS, Cervellione RM, Cheng W, Wilkins S, Gearhart JP, Sirchia F, Di Grazia M, Ebert AK, Rösch W, Ellinger J, Jenetzky E, Zwink N, Feitz WF, Marcelis C, Schumacher J, Martinón-Torres F, Hibberd ML, Khor CC, Heilmann-Heimbach S, Barth S, Boyadjiev SA, Brusco A, Ludwig M, Newman W, Nordenskjöld A, Yamada G, Odermatt B, Reutter H.

Sci Rep. 2017 Feb 8;7:42170. doi: 10.1038/srep42170.

25.

Construction of a BioBrick™ compatible vector system for Rhodococcus.

Ellinger J, Schmidt-Dannert C.

Plasmid. 2017 Mar;90:1-4. doi: 10.1016/j.plasmid.2017.01.004. Epub 2017 Jan 24.

PMID:
28130036
26.

Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma.

Ellinger J, Poss M, Brüggemann M, Gromes A, Schmidt D, Ellinger N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC.

Clin Genitourin Cancer. 2017 Aug;15(4):e551-e562. doi: 10.1016/j.clgc.2016.11.010. Epub 2016 Dec 1.

PMID:
28063846
27.

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.

Uhl B, Gevensleben H, Tolkach Y, Sailer V, Majores M, Jung M, Meller S, Stein J, Ellinger J, Dietrich D, Kristiansen G.

J Mol Diagn. 2017 Jan;19(1):107-114. doi: 10.1016/j.jmoldx.2016.08.008. Epub 2016 Dec 8.

PMID:
27939865
28.

Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma.

Nientiedt M, Deng M, Schmidt D, Perner S, Müller SC, Ellinger J.

Sci Rep. 2016 Nov 24;6:37158. doi: 10.1038/srep37158.

29.

Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.

Goltz D, Gevensleben H, Dietrich J, Ellinger J, Landsberg J, Kristiansen G, Dietrich D.

Oncoimmunology. 2016 Sep 2;5(10):e1221555. eCollection 2016.

30.

Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma.

Ellinger J, Gromes A, Poss M, Brüggemann M, Schmidt D, Ellinger N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC.

Oncotarget. 2016 Dec 27;7(52):86490-86499. doi: 10.18632/oncotarget.13275.

31.

PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.

Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J, Dietrich D, Kristiansen G.

Oncotarget. 2016 Nov 29;7(48):79943-79955. doi: 10.18632/oncotarget.13161.

32.

PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.

Holmes EE, Goltz D, Sailer V, Jung M, Meller S, Uhl B, Dietrich J, Röhler M, Ellinger J, Kristiansen G, Dietrich D.

Clin Epigenetics. 2016 Sep 26;8:104. doi: 10.1186/s13148-016-0270-x. eCollection 2016.

33.

CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.

Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, Stein J, Sailer V, Jung M, Kristiansen G, Dietrich D.

Epigenetics. 2016 Dec;11(12):871-880. Epub 2016 Sep 30.

34.

The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma.

Ellinger J, Gevensleben H, Müller SC, Dietrich D.

Expert Rev Mol Diagn. 2016 Oct;16(10):1059-1065. Epub 2016 Sep 27. Review.

PMID:
27649770
35.

Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients.

Ellinger J, Schneider AC, Bachmann A, Kristiansen G, Müller SC, Rogenhofer S.

Anticancer Res. 2016 Aug;36(8):3961-4.

PMID:
27466500
36.

CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.

Goltz D, Holmes EE, Gevensleben H, Sailer V, Dietrich J, Jung M, Röhler M, Meller S, Ellinger J, Kristiansen G, Dietrich D.

Oncotarget. 2016 Aug 16;7(33):53309-53320. doi: 10.18632/oncotarget.10786.

37.

Testicular seminoma clinical stage 1: treatment outcome on a routine care level.

Dieckmann KP, Dralle-Filiz I, Matthies C, Heinzelbecker J, Bedke J, Ellinger J, Anheuser P, Souchon R, Pichlmeier U; German Testicular Cancer Study Group.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1599-607. doi: 10.1007/s00432-016-2162-z. Epub 2016 Apr 26.

38.

Seminoma Clinical Stage 1 - Patterns of Care in Germany.

Dieckmann KP, Dralle-Filiz I, Heinzelbecker J, Matthies C, Bedke J, Ellinger J, Sommer J, Haben B, Souchon R, Anheuser P, Pichlmeier U.

Urol Int. 2016;96(4):390-8. doi: 10.1159/000443214. Epub 2016 Apr 20.

39.

Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.

Syring I, Klümper N, Offermann A, Braun M, Deng M, Boehm D, Queisser A, von Mässenhausen A, Brägelmann J, Vogel W, Schmidt D, Majores M, Schindler A, Kristiansen G, Müller SC, Ellinger J, Shaikhibrahim Z, Perner S.

Oncotarget. 2016 Apr 26;7(17):23043-55. doi: 10.18632/oncotarget.8469.

40.

Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report.

Stein J, Latz S, Ellinger J, Hauser S, Sailer V, Oelmann-Avendano J, Marx C, Brossart P, Wolf D, Müller SC.

Urol Int. 2016;97(3):369-372. Epub 2016 Apr 2.

PMID:
27035919
41.

Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.

Schrödter S, Braun M, Syring I, Klümper N, Deng M, Schmidt D, Perner S, Müller SC, Ellinger J.

Mol Cancer. 2016 Feb 2;15:10. doi: 10.1186/s12943-016-0495-5.

42.

NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival.

Müller FE, Braun M, Syring I, Klümper N, Schmidt D, Perner S, Hauser S, Müller SC, Ellinger J.

Am J Cancer Res. 2015 Aug 15;5(9):2816-22. eCollection 2015.

43.

The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma.

Ellinger J, Alam J, Rothenburg J, Deng M, Schmidt D, Syring I, Miersch H, Perner S, Müller SC.

Am J Cancer Res. 2015 Aug 15;5(9):2799-807. eCollection 2015.

44.

The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.

Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, Majores M, Stein J, Uhl B, Müller S, Ellinger J, Stephan C, Jung K, Brossart P, Kristiansen G.

Clin Cancer Res. 2016 Apr 15;22(8):1969-77. doi: 10.1158/1078-0432.CCR-15-2042. Epub 2015 Nov 16.

45.

Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling.

Deng M, Blondeau JJ, Schmidt D, Perner S, Müller SC, Ellinger J.

Genom Data. 2015 Jun 14;5:173-5. doi: 10.1016/j.gdata.2015.06.016. eCollection 2015 Sep.

46.

Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors.

Klümper N, Syring I, Offermann A, Shaikhibrahim Z, Vogel W, Müller SC, Ellinger J, Strauß A, Radzun HJ, Ströbel P, Brägelmann J, Perner S, Bremmer F.

Diagn Pathol. 2015 Sep 17;10:165. doi: 10.1186/s13000-015-0398-6.

47.

Cytoplasmatic and Nuclear YAP1 and pYAP1 Staining in Urothelial Bladder Cancer.

Latz S, Umbach T, Goltz D, Kristiansen G, Müller SC, Ellinger J.

Urol Int. 2016;96(1):39-45. doi: 10.1159/000438868. Epub 2015 Aug 20.

PMID:
26287745
48.

Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta.

Aziz A, Gierth M, Rink M, Schmid M, Chun FK, Dahlem R, Roghmann F, Palisaar RJ, Noldus J, Ellinger J, Müller SC, Pycha A, Martini T, Bolenz C, Moritz R, Herrmann E, Keck B, Wullich B, Mayr R, Fritsche HM, Burger M, Bastian PJ, Seitz C, Brookman-May S, Xylinas E, Shariat SF, Fisch M, May M; PROMETRICS 2011 Research Group.

World J Urol. 2015 Dec;33(12):1945-50. doi: 10.1007/s00345-015-1572-x. Epub 2015 May 7.

PMID:
25947885
49.

Scaffold-fused riboregulators for enhanced gene activation in Synechocystis sp. PCC 6803.

Sakai Y, Abe K, Nakashima S, Ellinger JJ, Ferri S, Sode K, Ikebukuro K.

Microbiologyopen. 2015 Aug;4(4):533-40. doi: 10.1002/mbo3.257. Epub 2015 Apr 10.

50.

Epigenetic biomarkers in the blood of patients with urological malignancies.

Ellinger J, Müller SC, Dietrich D.

Expert Rev Mol Diagn. 2015 Apr;15(4):505-16. doi: 10.1586/14737159.2015.1019477. Epub 2015 Feb 26. Review.

PMID:
25719388

Supplemental Content

Loading ...
Support Center